Famciclovir Tablets (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer this drug 250 mg orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer this drug 125 mg orally 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this drug 250 mg orally 2 times daily. Temporarily discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the creatinine clearance of this drug is reduced in patients with renal impairment, dose adjustment should be undertaken with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose, 2 times daily 10～29 250 mg per dose, once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 125 mg per dose, 2 times daily 10～29 125 mg per dose, once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose, 2 times daily 10～29 125 mg per dose, 2 times daily 4) If only the serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, it is preferable to administer the drug every 48 hours, taking the dialysis interval into account. Since 4 hours of hemodialysis reduces the plasma concentration of this drug by approximately 75%, administer this drug immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is required in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This drug should not be used in patients who have had hypersensitivity reactions to this drug or its active ingredient, penciclovir. Additionally, since this drug contains lactose, it should not be administered to patients with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients with renal function issues must exercise special caution when using this drug, and dose adjustments may be necessary as needed. While taking this medication, side effects such as headache, nausea, vomiting, abdominal pain, diarrhea, skin rash, and itching may occur, and if symptoms are severe or persistent, consultation with a healthcare provider is advisable. Furthermore, this drug does not cure genital herpes; if symptoms appear during treatment, it is recommended to avoid sexual contact and maintain safe sexual relations. If symptoms such as dizziness, drowsiness, or confusion occur while taking the drug, driving or operating machinery should be avoided. Patients with mild to moderate hepatic impairment do not require dose adjustments, but caution is advised as the drug’s efficacy may be reduced in patients with severe liver impairment. This drug has low potential for drug interactions, but caution is needed when co-administered with drugs such as probenecid, as it may increase blood concentration and lead to toxicity. Women who are pregnant or breastfeeding should only use this drug based on a doctor's judgment as its safety has not been fully established. Children under the age of 18 are advised not to use this drug as its safety and efficacy have not been confirmed. Older adults may require dose adjustments if there are renal function issues. In case of overdose, appropriate treatment should be provided, and dialysis may be helpful, so immediate contact with a medical institution is necessary. This drug should be stored in a tightly sealed container to avoid exposure to air or moisture, and it is best kept in a dry place at or below 30 degrees Celsius. This helps to maintain the drug's effectiveness for a longer period.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This drug should be stored in a tightly sealed container to prevent exposure to air and moisture. It is best stored in a dry place at or below 30 degrees Celsius. This will help maintain the drug's effectiveness for a longer period.

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle